Literature DB >> 12493344

Pharmacologic perspective on the physiology of the lower urinary tract.

Karl-Erik Andersson1, Petter Hedlund.   

Abstract

Myogenic activity, distention of the detrusor, and signals from the urothelium may initiate voiding. In the bladder, afferent nerves have been identified not only in the detrusor, but also suburothelially, where they form a plexus that lies immediately beneath the epithelial lining. Extracellular adenosine triphosphate (ATP) has been found to mediate excitation of small-diameter sensory neurons via P2X3 receptors, and it has been shown that bladder distention causes release of ATP from the urothelium. In turn, ATP can activate P2X3 receptors on suburothelial afferent nerve terminals to evoke a neural discharge. However, most probably, not only ATP but also a cascade of inhibitory and stimulatory transmitters and mediators are involved in the transduction mechanisms underlying the activation of afferent fibers during bladder filling. These mechanisms may be targets for future drugs. The central nervous control of micturition involves many transmitter systems, which may be suitable targets for pharmacologic intervention. gamma-Aminobutyric acid, dopamine, enkephalin, serotonin, and noradrenaline receptors and mechanisms are known to influence micturition, and potentially, drugs that affect these systems could be developed for clinical use. However, a selective action on the lower urinary tract may be difficult to obtain. Most drugs currently used for treatment of detrusor overactivity have a peripheral site of action, mainly the efferent (cholinergic) neurotransmission and/or the detrusor muscle itself. In the normal bladder, muscarinic receptor stimulation produces the main part of detrusor contraction, but evidence is accumulating that in disease states, such as neurogenic bladders, outflow obstruction, idiopathic detrusor instability, and interstitial cystitis, as well as in the aging bladder, a noncholinergic activation via purinergic receptors may occur. If this component of activation is responsible not only for part of the bladder contractions, but also for the symptoms of the overactive bladder, it should be considered an important target for therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12493344     DOI: 10.1016/s0090-4295(02)01786-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  32 in total

Review 1.  Mechanisms of disease: involvement of the urothelium in bladder dysfunction.

Authors:  Lori A Birder; William C de Groat
Journal:  Nat Clin Pract Urol       Date:  2007-01

Review 2.  The bladder epithelium and overactive bladder: what we know.

Authors:  Courtenay K Moore; Howard B Goldman
Journal:  Curr Urol Rep       Date:  2006-11       Impact factor: 3.092

Review 3.  Drug-induced urinary retention: incidence, management and prevention.

Authors:  Katia M C Verhamme; Miriam C J M Sturkenboom; Bruno H Ch Stricker; Ruud Bosch
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  Bladder dysfunction and altered somatic sensitivity in PACAP-/- mice.

Authors:  Victor May; Margaret A Vizzard
Journal:  J Urol       Date:  2010-02       Impact factor: 7.450

5.  Management of urinary incontinence.

Authors:  George A Demaagd; Timothy C Davenport
Journal:  P T       Date:  2012-06

6.  Role of Purinergic Signaling in Voiding Dysfunction.

Authors:  Yan Sun; Toby C Chai
Journal:  Curr Bladder Dysfunct Rep       Date:  2010-08-26

Review 7.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

8.  Detrusor contractility to parasympathetic mediators is differentially altered in the compensated and decompensated states of diabetic bladder dysfunction.

Authors:  Nicole S Klee; Robert S Moreland; Derek M Kendig
Journal:  Am J Physiol Renal Physiol       Date:  2019-05-29

Review 9.  Trospium chloride in the management of overactive bladder.

Authors:  Eric S Rovner
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats.

Authors:  Katsuaki Ito; Akihito Iwami; Hiromi Katsura; Masahiro Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-05       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.